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males are thought to be DMD carriers. Approximately 2.5-7.8% of 
female DMD carriers have muscle weakness and are categorized 
as manifesting DMD carriers.1, 2, 4) Therefore, here we reviewed 
recent studies to meet the need for a better understanding about 
the characterization of female carriers of DMD.
What is dystrophinopathies?
Duchenne’s description of DMD was published in 1861. He 
referred to the disease as “hypertrophic paraplegia of infancy 
due to a cerebral cause”.5) However, in 1868, he performed muscle 
biopsies and recognized that it was of muscular origin. He 
proposed the criteria for diagnosing this disease and reported the 
results of muscle biopsy which showed replacement of muscle 
by fat and connective tissue.6) Gowers, in 1886, noted that cases 
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Introduction
Duchenne muscular dystrophy (DMD) is a recessive X-linked 
form of muscular dystrophy. The milder form of this disease 
is called Becker muscular dystrophy(BMD).1) The disorder is 
also called dystrophinopathy because it caused by mutations 
in the DMD gene, which encodes dystrophin, on Xp21.2) Most 
heterozygous female carriers of DMD are subclinical. Therefore, 
identification of dystrophinopathy carriers may be only con­
sidered on clinical grounds such as clear X-linked family history 
of muscular dystrophy. However, myopathic muscle biopsy and 
advanced molecular diagnostic analysis can be used to identify 
the carrier state of DMD without a positive family history of 
dystrophinopathy , which is present in 10% of women with 
hyperCKemia.3) In addition, two-thirds of mothers of affected 
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Dystrophinopathy, caused by mutations in the DMD gene, presents with variable clinical phenotypes ranging from 
the severe Duchenne muscular dystrophy (DMD) to the milder Becker muscular dystrophy(BMD) forms. DMD is a 
recessive X-linked form of muscular dystrophy. Two-thirds of mothers of affected males are thought to be DMD carriers. 
Approximately 2.5-7.8% of female DMD carriers have muscle weakness and are categorized as manifesting DMD carriers. 
The symptoms of female carriers of DMD range from mild muscle weakness to severe gait problems. The most commonly 
presented symptom is mild proximal muscle weakness, which is often asymmetric and progressive, but shows variable 
clinical spectrum with BMD of more severe DMD-like phenotype. Atypical presentations in manifesting carriers are myalgia 
or cramps without limb weakness, isolated cardiomyopathy and camptocormia. Multiplex PCR and MLPA analysis are 
common techniques to identify mutations in the DMD gene. Relationship between X-chromosome inactivation and clinical 
severity is not clear. Female carriers of DMD are not less common, and they have an important role of birth of a male DMD.
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always occurred on the mother’s side of the family.7) Depending 
on the advancement of molecular genetics, mapping of the gene 
responsible for DMD was available to band p21 of the short arm 
of the X chromosome (Xp21).8-11) Subsequently, Kunkel’s group 
identified the muscle protein dystrophin which is encoded by 
the DMD gene.12) The full-size dystrophin is 427 kDa in molecular 
mass12) and its distribution is almost the same in both slow and 
fast fiber types.13) In addition, the extent of dystrophin expression 
is associated with clinical severity of dystrophinopathy 
patients.13) Dystrophin, located in the sarcolemma of muscle 
fibers, is almost absent in DMD and decreased in BMD. These 
advances were able to make diagnosis and genetic counseling 
more accurate.
Dystrophinopathies in female patients
Random inactivation of one of the two X chromosomes occurs 
during early embryonic development, leaving active 50% of the 
maternally derived chromosomes and 50% of the paternally 
derived ones.14) Non-random X-chromosome inactivation 
induce fewer than 50% of the nuclei which may have the nor­
mal dystrophin gene, resulting in clinical manifesting female 
carriers.15) Some reports described cases of X-autosomal 
translocations with breakpoints at Xp21 resulting in preferential 
inactivation of the normal chromosome.8, 11) If the X chromosome 
of turner syndrome patient (karyotype XO) carries a mutated 
dystrophin gene, her daughter can be symptomatic.
Clinical presentation of female carrier of DMD
DMD is the most common form of childhood muscular 
dystrophy, with an incidence of approximately 1 in 3,600-
6,000 live male births and a prevalence of approximately 3 
per 100,000.16, 17) The symptoms of DMD female carriers range 
from mild muscle weakness to severe gait problems. Although 
manifesting girls usually show much milder symptoms than 
boys, a few cases have disease severity similar to that seen in 
affected boys.3, 18, 19) The most commonly presented symptom 
is mild proximal muscle weakness, which is often asymmetric 
and progressive. There are variable clinical patterns from 
BMD-like to severe DMD-like phenotype.20) The prevalence of 
manifesting female carriers of DMD is slightly different in each 
study. Recent study reported 22% of female carriers manifested 
the symptoms, with 19% demonstrating muscle weakness 
measured by manual muscle testing and 8% presenting with 
dilated cardiomyopathy.21) A similar prevalence of females with 
symptoms was observed by other group, with 12% presenting 
with muscle weakness and 7% displaying cardiomyopathies.22) 
Some manifesting carriers only present myalgia or cramps 
without limb weakness.23) In addition, unusual cases such as 
isolated cardiomyopathy without skeletal muscle weakness24-26) 
and developmental delay in childhood have been reported.23) 
Also, there have been reports of manifesting carriers of DMD who 
initially presented with camptocormia which is forward flexion 
of the thoracolumbar spine that abates in the supine position.27)
Imaging evaluation of female carrier of DMD
Serum creatine kinase levels are commonly elevated in 
manifesting carriers of DMD.28) Magnetic resonance imaging 
(MRI) is performed for more comprehensive assessment of 
muscles. There was a report about elevation of reported proton 
spin lattice relaxation time (T1) in female carriers elevated in the 
gluteals, vastus lateralis, and gastrocnemius compared with the 
control group and correlation with the distribution of muscle 
edema.29) Elevated spin-spin or tranverse relaxation time (T2) in 
DMD carriers was also observed following muscle damage and 
inflammation/edema.30, 31) Quantitative MRI measures were 
used to evaluate muscle composition.32) In female carriers of 
DMD, there was considerable heterogeneity among lipid fraction 
measures compared with the control groups during 21 months 
of a longitudinal study.32) Although specific findings of imaging 
evaluation in female carriers of DMD has not yet been established, 
depending on the advance of neuroradiology, these invasive 
techniques could be strong tools for evaluation of carrier status.
Insights of diagnostic strategies of female carrier 
of DMD: diagnosis, novel pathological and genetic 
evidence 
1. Pathology
Muscle biopsy is used for diagnosis in cases of clinically 
suspicious of dystrophinopathy. It can provide information about 
the amount and molecular size if the protein is present. Muscle 
biopsy is usually not necessary when genetic testing is positive. 
However, pathological evidence is helpful for patients with a 
family history of DMD, but no family mutation is known.18)
Dystrophin labeling of muscle biopsies from manifesting carriers 
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shows a mosaic pattern, with reduced or absent dystrophin.33, 34) 
Immunohistochemistry findings are concordant with western 
blot analysis for dystrophin.34) No association is seen between 
the pattern of distribution of dystrophin and clinical severity of 
manifesting carriers.35) However, a few cases revealed that the 
absence of dystrophin expression and unstained fiber presumably 
affected the more severe phenotype.20) Moreover, dystrophin 
expression can vary in different muscle groups of DMD carriers.36)
2. Genetic test
The dystrophin gene have majority of deletion mutation, 
approximately 61.9-73% in western, northerm and Asian 
populations.37-39) The frequency of deletions of the DMD gene 
is greater in affected males resulting from a female gametic 
mutation (75%) than in those resulting from a male genetic 
mutation (56%).40) DMD gene partial duplications account for up 
to 6 % of DMD and BMD cases.41)
Dystrophin mutation is able to be detected by Multiplex PCR42) 
and multiplex ligation-dependent probe amplification (MLPA).43)
Multiplex PCR is a common technique to identify mutations of 
the DMD gene and can  detect approximately 98% of deletions.34) 
Since multiplex PCR is the least expensive and sensitive method, 
it is the first method of choice by clinicians when the patient is 
highly suspicious of DMD.41) Recently, several reports showed that 
MLPA is a more accurate method for mutation analysis of DMD 
than multiplex PCR. MLPA can detect the presence of deletions, 
duplication and abnormal DNA methylation. In particular, MLPA 
is the gold standard for molecular analysis of large number of 
genes.44) Therefore, if the patient is clinically suspected of DMD 
or is a female carrier of DMD but shows negative results from 
multiplex PCR, MLPA is recommend for mutation analysis.45) 
MLPA probes are sensitive to small changes within the sequence 
detected by the probe. A single nucleotide change very close to 
the probe ligation site can result in a decreased probe signal, thus 
mimicking a deletion.46) Therefore, it is strongly recommended 
to confirm all MLPA findings with another method, especially in 
cases of single probe deletions.46, 47)
Furthermore, dystrophin gene sequencing is used to analyze 
single-condition amplification/internal primers and multiplex 
amplifiable probe hybridization for detecting point mutations 
or small deletions/insertions if deletion/ duplication testing is 
negative.48, 49) 
Full characterisation of the mutation (deletion endpoints or 
exact position of any point mutation) is helpful to investigate 
the clinical variability of dystrophinopathy50, 51) and  recent trials 
about mutation-specific treatment.52-54)
3. X-chromosome inactivation (XCI)
Symptomatic carriers of DMD without chromosomal re­
arrangements have been explained by skewed X-chromosome 
inactivation related to preferential expression of the mutant 
allele.36, 55, 56) The nonrandom X-inactivation pattern of manifesting 
carriers of DMD showed derivative X remaining active as a saving 
mechanism against disease-expression.11, 57) Therefore, the extent 
of X-chromosome inactivation skewing is correlated with clinical 
phenotype.58) Nevertheless, some studies reported no significant 
association between X-chromosome inactivation pattern and 
clinical severity.59) Prognostic value of X-chromosome inactivation 
is also controversial.58, 60, 61)
Conclusion
Female carriers of DMD are not less common, and they have an 
important role in male DMD. Comprehension of characterization 
of female carriers of DMD is helpful for establishment of 
diagnostic approaches in patients who may have in the past been 
diagnosed as having autosomal recessive limb-girdle muscular 
dystrophy or unknown myopathy with a negative family history. 
References 
1.	 Moser	H,	Emery	AE.	The	manifesting	carrier	in	Duchenne	muscular	
dystrophy.	Clin	Genet	1974;5:271-84.
2.	 Norman	A,	Harper	P.	A	survey	of	manifesting	carriers	of	Duchenne	and	
Becker	muscular	dystrophy	in	Wales.	Clin	Genet	1989;36:31-7.
3.	 Hoffman	EP,	Arahata	K,	Minetti	C,	Bonilla	E,	Rowland	LP.	Dystrophin­
opathy	in	isolated	cases	of	myopathy	in	females.	Neurology	1992;42:	
967-75.
4.	 Taylor	PJ,	Maroulis	S,	Mullan	GL,	Pedersen	RL,	Baumli	A,	Elakis	G,	et	al.	
Measurement	of	the	clinical	utility	of	a	combined	mutation	detection	
protocol	in	carriers	of	Duchenne	and	Becker	muscular	dystrophy.	J	Med	
Genet	2007;44:368-72.
5.	 Duchenne	GB.	De	l'électrisation	localisée	et	de	son	application	à	la	
physiologie,	à	la	pathologie	et	à	la	thérapeutique.	2nd	Ed,	Paris:	Baillière,	
1861.
6.	 Duchenne	GB.	De	la	paralysie	musculaire	pseudo-hypertrophique	ou	
paralysie	myo-sclérosique.	Paris:	P.	Asselin,	1868.
7.	 Gowers	WR.	A	manual	of	diseases	of	the	nervous	system.	London:	
Churchill,	1886.
8.	 Greenstein	RM,	Reardon	MP,	Chan	TS,	Middleton	AB,	Mulivor	RA,	Greene	
AE,	et	al.	An	(X;11)	translocation	in	a	girl	with	Duchenne	muscular	
http://dx.doi.org/10.5734/JGM.2013.10.2.94 • J Genet Med 2013;10:94-98   97www.e-kjgm.org
dystrophy.	Repository	identification	No.	GM1695.	Cytogenet	Cell	Genet	
1980;27:268.
9.	 Davies	KE,	Pearson	PL,	Harper	PS,	Murray	JM,	O'Brien	T,	Sarfarazi	M,	
et	al.	Linkage	analysis	of	two	cloned	DNA	sequences	flanking	the	
Duchenne	muscular	dystrophy	locus	on	the	short	arm	of	the	human	X	
chromosome.	Nucleic	Acids	Res	1983;11:2303-12.
10.	 Francke	U,	Ochs	HD,	de	Martinville	B,	Giacalone	J,	Lindgren	V,	Disteche	
C,	et	al.	Minor	Xp21	chromosome	deletion	in	a	male	associated	with	
expression	of	Duchenne	muscular	dystrophy,	chronic	granulomatous	
disease,	retinitis	pigmentosa,	and	McLeod	syndrome.	Am	J	Hum	Genet	
1985;37:250-67.
11.	 Boyd	Y,	Buckle	V,	Holt	S,	Munro	E,	Hunter	D,	Craig	I.	Muscular	dystrophy	
in	girls	with	X;autosome	translocations.	J	Med	Genet	1986;23:484-90.
12.	 Hoffman	EP,	Brown	RH,	Jr.,	Kunkel	LM.	Dystrophin:	the	protein	product	
of	the	Duchenne	muscular	dystrophy	locus.	Cell	1987;51:919-28.
13.	 Culligan	KG,	Mackey	AJ,	Finn	DM,	Maguire	PB,	Ohlendieck	K.	Role	of	
dystrophin	isoforms	and	associated	proteins	in	muscular	dystrophy	
(review).	Int	J	Mol	Med	1998;2:639-48.
14.	 Matthews	PM,	Karpati	G.	Pattern	of	X-chromosome	inactivation	as	a	key	
determinant	of	the	clinicopathologic	phenotype	of	Duchenne	muscular	
dystrophy	carriers.	Neurology	1996;46:1189-91.
15.	 Pena	SD,	Karpati	G,	Carpenter	S,	Fraser	FC.	The	clinical	consequences	of	
X-chromosome	inactivation:	Duchenne	muscular	dystrophy	in	one	of	
monozygotic	twins.	J	Neurol	Sci	1987;79:337-44.
16.	 Bushby	K,	Finkel	R,	Birnkrant	DJ,	Case	LE,	Clemens	PR,	Cripe	L,	et	al.	
Diagnosis	and	management	of	Duchenne	muscular	dystrophy,	part	1:	
diagnosis,	and	pharmacological	and	psychosocial	management.	Lancet	
Neurol	2010;9:77-93.
17.	 Emery	AE.	Population	frequencies	of	inherited	neuromuscular	diseases-
-a	world	survey.	Neuromuscul	Disord	1991;1:19-29.
18.	 Bushby	KM,	Goodship	JA,	Nicholson	LV,	Johnson	MA,	Haggerty	
ID,	Gardner-Medwin	D.	Variability	in	clinical,	genetic	and	protein	
abnormalities	in	manifesting	carriers	of	Duchenne	and	Becker	muscular	
dystrophy.	Neuromuscul	Disord	1993;3:57-64.
19.	 Richards	CS,	Watkins	SC,	Hoffman	EP,	Schneider	NR,	Milsark	IW,	Katz	
KS,	et	al.	Skewed	X	inactivation	in	a	female	MZ	twin	results	in	Duchenne	
muscular	dystrophy.	Am	J	Hum	Genet	1990;46:672-81.
20.	 Soltanzadeh	P,	Friez	MJ,	Dunn	D,	von	Niederhausern	A,	Gurvich	OL,	
Swoboda	KJ,	et	al.	Clinical	and	genetic	characterization	of	manifesting	
carriers	of	DMD	mutations.	Neuromuscul	Disord	2010;20:499-504.
21.	 Hoogerwaard	EM,	Bakker	E,	Ippel	PF,	Oosterwijk	JC,	Majoor-Krakauer	DF,	
Leschot	NJ,	et	al.	Signs	and	symptoms	of	Duchenne	muscular	dystrophy	
and	Becker	muscular	dystrophy	among	carriers	in	The	Netherlands:	a	
cohort	study.	Lancet	1999;353:2116-9.
22.	 Grain	L,	Cortina-Borja	M,	Forfar	C,	Hilton-Jones	D,	Hopkin	J,	Burch	
M.	Cardiac	abnormalities	and	skeletal	muscle	weakness	in	carriers	of	
Duchenne	and	Becker	muscular	dystrophies	and	controls.	Neuromuscul	
Disord	2001;11:186-91.
23.	 Ceulemans	BP,	Storm	K,	Reyniers	E,	Jr.,	Callewaert	L,	Martin	JJ.	Muscle	
pain	as	the	only	presenting	symptom	in	a	girl	with	dystrophinopathy.	
Pediatr	Neurol	2008;38:64-6.
24.	 Kinoshita	H,	Goto	Y,	Ishikawa	M,	Uemura	T,	Matsumoto	K,	Hayashi	
YK,	et	al.	A	carrier	of	Duchenne	muscular	dystrophy	with	dilated	
cardiomyopathy	but	no	skeletal	muscle	symptom.	Brain	Dev	1995;17:	
202-5.
25.	 Mirabella	M,	Servidei	S,	Manfredi	G,	Ricci	E,	Frustaci	A,	Bertini	E,	et	al.	
Cardiomyopathy	may	be	the	only	clinical	manifestation	in	female	
carriers	of	Duchenne	muscular	dystrophy.	Neurology	1993;43:2342-5.
26.	 Walcher	T,	Kunze	M,	Steinbach	P,	Sperfeld	AD,	Burgstahler	C,	Hombach	
V,	et	al.	Cardiac	involvement	in	a	female	carrier	of	Duchenne	muscular	
dystrophy.	Int	J	Cardiol	2010;138:302-5.
27.	 Findlay	AR,	Lewis	S,	Sahenk	Z,	Flanigan	KM.	Camptocormia	as	a	late	
presentation	in	a	manifesting	carrier	of	duchenne	muscular	dystrophy.	
Muscle	Nerve	2013;47:124-7.
28.	 Griggs	RC,	Mendell	JR,	Brooke	MH,	Fenichel	GM,	Miller	JP,	Province	M,	et	
al.	Clinical	investigation	in	Duchenne	dystrophy:	V.	Use	of	creatine	kinase	
and	pyruvate	kinase	in	carrier	detection.	Muscle	Nerve	1985;8:60-7.
29.	 Matsumura	K,	Nakano	I,	Fukuda	N,	Ikehira	H,	Tateno	Y,	Aoki	Y.	Duchenne	
muscular	dystrophy	carriers.	Proton	spin-lattice	relaxation	times	of	
skeletal	muscles	on	magnetic	resonance	imaging.	Neuroradiology	
1989;31:373-6.
30.	 Foley	JM,	Jayaraman	RC,	Prior	BM,	Pivarnik	JM,	Meyer	RA.	MR	measure-
ments	of	muscle	damage	and	adaptation	after	eccentric	exercise.	J	Appl	
Physiol	(1985)	1999;87:2311-8.
31.	 Mathur	S,	Vohra	RS,	Germain	SA,	Forbes	S,	Bryant	ND,	Vandenborne	K,	
et	al.	Changes	in	muscle	T2	and	tissue	damage	after	downhill	running	in	
mdx	mice.	Muscle	Nerve	2011;43:878-86.
32.	 Forbes	SC,	Lott	DJ,	Finkel	RS,	Senesac	C,	Byrne	BJ,	Sweeney	HL,	et	al.	MRI/
MRS	evaluation	of	a	female	carrier	of	Duchenne	muscular	dystrophy.	
Neuromuscul	Disord	2012;22	Suppl	2:S111-21.
33.	 Arahata	K,	Ishihara	T,	Kamakura	K,	Tsukahara	T,	Ishiura	S,	Baba	C,	et	al.	
Mosaic	expression	of	dystrophin	in	symptomatic	carriers	of	Duchenne's	
muscular	dystrophy.	N	Engl	J	Med	1989;320:138-42.
34.	 Na	SJ,	Kim	WJ,	Kim	SM,	Lee	KO,	Yoon	B,	Choi	YC.	Clinical,	immuno-
histochemical,	Western	blot,	and	genetic	analysis	in	dystrophinopathy.	J	
Clin	Neurosci	2013;20:1099-105.
35	 Hoogerwaard	EM,	Ginjaar	IB,	Bakker	E,	de	Visser	M.	Dystrophin	analysis	
in	carriers	of	Duchenne	and	Becker	muscular	dystrophy.	Neurology	
2005;65:1984-6.
36.	 Azofeifa	J,	Voit	T,	Hubner	C,	Cremer	M.	X-chromosome	methylation	in	
manifesting	and	healthy	carriers	of	dystrophinopathies:	concordance	
of	activation	ratios	among	first	degree	female	relatives	and	skewed	
inactivation	as	cause	of	the	affected	phenotypes.	Hum	Genet	1995;96:	
167-76.
37.	 Singh	V,	Sinha	S,	Mishra	S,	Chaturvedi	LS,	Pradhan	S,	Mittal	RD,	et	al.	
Proportion	and	pattern	of	dystrophin	gene	deletions	in	north	Indian	
Duchenne	and	Becker	muscular	dystrophy	patients.	Hum	Genet	
1997;99:206-8.
98      YN Cho and YC Choi • Female Carriers of Duchenne Muscular Dystrophy www.e-kjgm.org
38.	 Lai	PS,	Takeshima	Y,	Adachi	K,	Van	Tran	K,	Nguyen	HT,	Low	PS,	et	al.	
Comparative	study	on	deletions	of	the	dystrophin	gene	in	three	Asian	
populations.	J	Hum	Genet	2002;47:552-5.
39.	 Khalap	N,	Joshi	V,	Ladiwalla	U,	Khadilkar	S,	Mahajan	S.	A	report	on	higher	
frequency	of	DMD	gene	deletion	in	the	Indian	subcontinent.	Indian	J	
Hum	Genet	1997;3:117-20.
40.	 Baumbach	LL,	Chamberlain	JS,	Ward	PA,	Farwell	NJ,	Caskey	CT.	Molecular	
and	clinical	correlations	of	deletions	leading	to	Duchenne	and	Becker	
muscular	dystrophies.	Neurology	1989;39:465-74.
41.	 Hu	X,	Ray	PN,	Murphy	EG,	Thompson	M,	Worton	R.	Duplicational	
mutation	at	the	Duchenne	muscular	dystrophy	locus:	its	frequency,	
distribution,	origin,	and	phenotypegenotype	correlation.	Am	J	Hum	
Genet	1990;46:682-95.
42.	 Prior	TW,	Bridgeman	SJ.	Experience	and	strategy	for	the	molecular	
testing	of	Duchenne	muscular	dystrophy.	J	Mol	Diagn	2005;7:317-26.
43.	 Lalic	T,	Vossen	RH,	Coffa	J,	Schouten	JP,	Guc-Scekic	M,	Radivojevic	D,	et	
al.	Deletion	and	duplication	screening	in	the	DMD	gene	using	MLPA.	Eur	
J	Hum	Genet	2005;13:1231-4.
44.	 Stuppia	L,	Antonucci	I,	Palka	G,	Gatta	V.	Use	of	the	MLPA	Assay	in	the	
Molecular	Diagnosis	of	Gene	Copy	Number	Alterations	in	Human	
Genetic	Diseases.	Int	J	Mol	Sci	2012;13:3245-76.
45.	 Song	TJ,	Lee	KA,	Kang	SW,	Cho	H,	Choi	YC.	Three	cases	of	manifesting	
female	carriers	in	patients	with	Duchenne	muscular	dystrophy.	Yonsei	
Med	J	2011;52:192-5.
46.	 Cho	H,	Hong	JM,	Lee	KA,	Choi	YC.	Clinical	usefulness	of	molecular	
diagnosis	in	dystrophin	gene	mutations	using	the	multiplex	ligation-
dependent	probe	amplification	(MLPA)	method.	J	Korean	Neurol	Assoc	
2010;28:22-6.
47.	 Sellner	LN,	Taylor	GR.	MLPA	and	MAPH:	new	techniques	for	detection	of	
gene	deletions.	Hum	Mutat	2004;23:413-9.
48.	 Flanigan	KM,	von	Niederhausern	A,	Dunn	DM,	Alder	J,	Mendell	JR,	Weiss	
RB.	Rapid	direct	sequence	analysis	of	the	dystrophin	gene.	Am	J	Hum	
Genet	2003;72:931-9.
49.	 Dent	KM,	Dunn	DM,	von	Niederhausern	AC,	Aoyagi	AT,	Kerr	L,	Bromberg	
MB,	et	al.	Improved	molecular	diagnosis	of	dystrophinopathies	in	an	
unselected	clinical	cohort.	Am	J	Med	Genet	A	2005;134:295-8.
50.	 Yasuma	F,	Konagaya	M,	Sakai	M,	Kuru	S,	Kawamura	T.	A	new	lease	on	
life	for	patients	with	Duchenne	muscular	dystrophy	in	Japan.	Am	J	Med	
2004;117:363.
51.	 Jeppesen	J,	Green	A,	Steffensen	BF,	Rahbek	J.	The	Duchenne	muscular	
dystrophy	population	in	Denmark,	1977-2001:	prevalence,	incidence	
and	survival	in	relation	to	the	introduction	of	ventilator	use.	
Neuromuscul	Disord	2003;13:804-12.
52.	 Lim	LE,	Rando	TA.	Technology	insight:	therapy	for	Duchenne	muscular	
dystrophy-an	opportunity	for	personalized	medicine?	Nat	Clin	Pract	
Neurol	2008;4:149-58.
53.	 van	Ommen	GJ,	van	Deutekom	J,	Aartsma-Rus	A.	The	therapeutic	
potential	of	antisense-mediated	exon	skipping.	Curr	Opin	Mol	Ther	
2008;10:140-9.
54.	 van	Deutekom	JC,	Janson	AA,	Ginjaar	IB,	Frankhuizen	WS,	Aartsma-Rus	
A,	Bremmer-Bout	M,	et	al.	Local	dystrophin	restoration	with	antisense	
oligonucleotide	PRO051.	N	Engl	J	Med	2007;357:2677-86.
55.	 Yoshioka	M,	Yorifuji	T,	Mituyoshi	I.	Skewed	X	inactivation	in	manifesting	
carriers	of	Duchenne	muscular	dystrophy.	Clin	Genet	1998;53:102-7.
56.	 Pegoraro	E,	Schimke	RN,	Arahata	K,	Hayashi	Y,	Stern	H,	Marks	H,	et	al.	
Detection	of	new	paternal	dystrophin	gene	mutations	in	isolated	cases	
of	dystrophinopathy	in	females.	Am	J	Hum	Genet	1994;54:989-1003.
57.	 Wenger	SL,	Steele	MW,	Hoffman	EP,	Barmada	MA,	Wessel	HB.	X	
inactivation	and	dystrophin	studies	in	a	t(X;12)	female:	evidence	for	
biochemical	normalization	in	Duchenne	muscular	dystrophy	carriers.	
Am	J	Med	Genet	1992;43:1012-5.
58.	 Juan-Mateu	J,	Rodriguez	MJ,	Nascimento	A,	Jimenez-Mallebrera	C,	
Gonzalez-Quereda	L,	Rivas	E,	et	al.	Prognostic	value	of	X-chromosome	
inactivation	in	symptomatic	female	carriers	of	dystrophinopathy.	
Orphanet	J	Rare	Dis	2012;7:82.
59.	 Brioschi	S,	Gualandi	F,	Scotton	C,	Armaroli	A,	Bovolenta	M,	Falzarano	
MS,	et	al.	Genetic	characterization	in	symptomatic	female	DMD	carriers:	
lack	of	relationship	between	X-inactivation,	transcriptional	DMD	allele	
balancing	and	phenotype.	BMC	Med	Genet	2012;13:73.
60.	 Matthews	PM,	Benjamin	D,	Van	Bakel	I,	Squier	MV,	Nicholson	LV,	Sewry	
C,	et	al.	Muscle	X-inactivation	patterns	and	dystrophin	expression	in	
Duchenne	muscular	dystrophy	carriers.	Neuromuscul	Disord	1995;5:	
209-20.
61.	 Sumita	DR,	Vainzof	M,	Campiotto	S,	Cerqueira	AM,	Canovas	M,	Otto	PA,	
et	al.	Absence	of	correlation	between	skewed	X	inactivation	in	blood	and	
serum	creatine-kinase	levels	in	Duchenne/Becker	female	carriers.	Am	J	
Med	Genet	1998;80:356-61.
